Vanda Pharmaceuticals Inc. (VNDA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs. The company's commercial portfolio includes Fanapt (bipolar I/schizophrenia), HETLIOZ (Non-24/SMS), PONVORY (multiple sclerosis), and NEREUS (motion sickness), which launched commercially in the U.S. in May 2026. BYSANTI received FDA approval in Q1 2026 for bipolar I and schizophrenia, with a commercial launch expected in the second half of 2026.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Product Sales | $50,529 | $52,590 | $102,247 | $102,631 |
| Net Loss | $(62,513) | $(27,207) | $(111,080) | $(56,701) |
| Net Loss Per Share (Diluted) | $(1.04) | $(0.46) | $(1.86) | $(0.96) |
| Operating Expenses | $114,338 | $91,093 | $216,280 | $182,162 |
| Cash & Cash Equivalents | $55,882 | $84,851 | $55,882 | $84,851 |
| Marketable Securities | $114,147 | $178,996 | $114,147 | $178,996 |
| Total Liquidity | $170,029 | $263,847 | $170,029 | $263,847 |
Product Revenue Breakdown (Q2 2026): Fanapt ($36.0M), HETLIOZ ($5.6M), PONVORY ($7.9M), and NEREUS ($1.0M).
Material Changes vs. Prior Period
- Revenue: Total revenue decreased 4% in Q2 2026 compared to Q2 2025. This was driven by a 66% decline in HETLIOZ sales due to generic competition and inventory destocking, partially offset by a 23% increase in Fanapt sales and the initial launch of NEREUS.
- Expenses: Operating expenses increased significantly. Research and Development (R&D) expenses rose 68% to $37.0M, driven by higher spending on VQW-765 and other development programs. Selling, General, and Administrative (SG&A) expenses increased 11% to $71.8M due to commercial launch activities for NEREUS and sales force expansion.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased by approximately $93.8 million from year-end 2025 to $170.0 million as of June 30, 2026. This reduction reflects a net cash outflow from operating activities of $81.3 million for the six-month period.
- Intangible Assets: Amortization expense increased due to the capitalization and amortization of the NEREUS intangible asset following its FDA approval in late 2025.
Guidance, Outlook, and Risks
- Outlook: Management believes current cash and marketable securities, combined with product sales, will be sufficient to fund operations for at least the next 12 months. The company is proceeding with the commercial launch of BYSANTI and the ongoing launch of NEREUS.
- Regulatory & Clinical: Key upcoming milestones include topline results for NEREUS (GLP-1 induced vomiting), VQW-765 (social anxiety), and HETLIOZ (DSPD) in 2026. The BLA for Quimilza (GPP) is under FDA review with a PDUFA date of December 12, 2026.
- Legal Risks: The company is engaged in extensive litigation regarding HETLIOZ generic competition (Teva, Apotex, MSN) and FDA regulatory actions. A trial regarding HETLIOZ patent infringement is scheduled for October 2026. Additionally, the company is challenging FDA decisions regarding HETLIOZ (jet lag) and NEREUS (gastroparesis) approvals.
- Trade Risks: A new 100% tariff on imported patented pharmaceutical products and APIs is effective July 31, 2026, for large pharma companies. While exemptions exist for orphan drugs, the company relies on third-party manufacturers outside the U.S., creating potential cost and margin risks.
- Revenue Constraints: NEREUS revenue is currently constrained due to uncertainties regarding patient demand and potential product returns from wholesaler stocking.
Investor Verification Checklist
- HETLIOZ Decline: Verify the sustainability of the 66% Q2 revenue drop in HETLIOZ and the impact of ongoing generic competition on future cash flows.
- NEREUS Launch: Assess the timeline for releasing constrained revenue and the success of the direct-to-consumer model versus wholesaler stocking.
- BYSANTI Launch: Confirm the commercial launch timeline for BYSANTI in H2 2026 and associated capital requirements.
- Legal Exposure: Monitor the October 2026 trial date for HETLIOZ patent litigation and the status of FDA administrative hearings for HETLIOZ (jet lag) and NEREUS (gastroparesis).
- Tariff Impact: Evaluate the company's exposure to the new 100% import tariffs effective July 31, 2026, and the likelihood of securing orphan drug exemptions.
- Cash Burn: Review the $81.3M operating cash burn for the first half of 2026 against the $170M liquidity position to assess runway without additional financing.